Stock GRTS GRITSTONE BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Gritstone bio, Inc.

Equities

GRTS

US39868T1051

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
0.7737 USD +3.66% Intraday chart for Gritstone bio, Inc. -3.48% -62.07%
Jun. 01 Certain Restricted Stock Units of Gritstone bio, Inc. are subject to a Lock-Up Agreement Ending on 1-JUN-2024. CI
Jun. 01 Certain Stock Options of Gritstone bio, Inc. are subject to a Lock-Up Agreement Ending on 1-JUN-2024. CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Certain Restricted Stock Units of Gritstone bio, Inc. are subject to a Lock-Up Agreement Ending on 1-JUN-2024.
CI
Certain Stock Options of Gritstone bio, Inc. are subject to a Lock-Up Agreement Ending on 1-JUN-2024.
CI
Certain Common Stock of Gritstone bio, Inc. are subject to a Lock-Up Agreement Ending on 1-JUN-2024.
CI
B. Riley Cuts Price Target on Gritstone bio to $3 From $6, Keeps Buy Rating
MT
Earnings Flash (GRTS) GRITSTONE BIO Posts Q1 Revenue $1.74M, vs. Street Est of $2.85M
MT
Transcript : Gritstone bio, Inc., Q1 2024 Earnings Call, May 09, 2024
Gritstone bio Reports First Quarter 2024 Financial Results and Provides Corporate Updates
GL
Gritstone bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Gritstone bio to Report First Quarter 2024 Financial Results and Provide Corporate Updates on May 9, 2024
AQ
Gritstone bio Highlights the Durability and Potential Broad Utility of its Self-amplifying mRNA (samRNA) COVID-19 Vaccine at ESCMID Global 2024
AQ
Gritstone Bio, Inc. Highlights the Durability and Potential Broad Utility of its Self-amplifying mRNA Vaccine at ESCMID Global 2024
CI
Gritstone bio Announces Appointment of Stephen Webster to its Board of Directors
AQ
Gritstone Bio, Inc. Announces Board Changes
CI
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS
PR
Nature Medicine Publishes Interim Results from Gritstone bio's Phase 1/2 Study of 'Off-the-Shelf' Neoantigen Vaccine Platform
AQ
Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of “Off-the-Shelf” Neoantigen Vaccine Platform (SLATE)
AQ
Nature Medicine Publishes Interim Results from Gritstone Bio's Phase 1/2 Study of "Off-The-Shelf" Neoantigen Vaccine Platform
CI
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS
PR
Gritstone bio to Participate in Upcoming Investor and Scientific Conferences
AQ
Gritstone bio Presents Improvements to EDGE™ Platform at AACR 2024
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GRTS Stock
  4. News Gritstone bio, Inc.